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Novel phosphate derivatives of the and-HIV nucleoside anulogue AZT have been prepared by phosphorochloridate chemistry. In particular, 
phosphates carrying ester-containing side-chains are described. These materials arc designed 10 act as membrane-soluble prodrugsof the bio-active 
free nucleotides. In vitro evaluation revealed the compounds to have a pronounced, selective anliviral activity. In several cases the phosphate 
derivatives are more seieclive in their aclhl than the parent nucleoside AZT. In particular, this arises from the low toxicity of the phosphate 
pro-drugs by comparison to AZT. These data support he suggestion thal the phosphate derivatives exert their biological effects via intracellular 
release of the nuclcotide forms, and suggests that such pro-drug forms may be worthy of further study. 
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1. INTRODUCTION 2. MATERlALS AND METHODS 
The nucleoside analogue 3’-azido-3’-dcoxythymidine 
(AZT, 1) is a potent inhibitor of human immunodefi- 
ciency virus (HIVl) proliferation [l], and is now 
established as a useful treatment for acquired immu- 
nodeficiency syndrome (AIDS). As with other chemo- 
therapeutic nucleoside analogues, AZT acts only after 
metabolic activation to its S-phosphate forms. This de- 
pendence on (kinase mediated) phosphorylation may be 
a limitation; especially in cellular environments low in 
particular nucleoside kinase activities. 
We have previously outlined the potential advantages 
of utilising masked phosphate derivatives of anti-cancer 
and anti-herpetic nucleoside analogues [2,3]. We have 
found that simple dialkyl phosphate derivatives of 
AZT, and other nucleoside analogues, are inactive as 
anti-HIV agents [4], whereas ubstituted ialkyl phos- 
phates (2a-b) are active [5]. In this paper we report the 
preparation of novel estercontaining phosphate deriva- 
tives of AZT, which selectively inhibit the replication of 
HIV. In particular, in contrast o AZT, the agents are 
selective, less toxic, antiviral agents in vitro. One of the 
products herein reported (3a) was recently described by 
us [6]. However, its activity is now described in a new 
assay, where it is included alongside new agents de- 
scribed here for the first time. 
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All reactions were carried out under scrupulously dry conditions, 
using generai procedures we have described [7j. P-31 NMR spectra 
were recorded on a Varian XL-200 spectrometer (82 MHz.) or a Jeal 
FX9OQ (36.2 MHz) and arc rcportecl in unita of 8 relative to 85% 
phosphoric acid as external standard, positive shii arc downfield. 
Carbon-13 NMR spectra were recorded on a Varian XL-200 s&xc- 
trometcr (50 MHz), a Varian VXR&O (100 MHz) or a Bruker 
AM3GO(90.6MHz)in unitsof6rclativeloCDCI,at77,000ppm.Both 
phosphorus-31 and carbon-l 3 NMR spectra were proton noiscdecou- 
pled and all signals were singlets unless otherwise stated. H-l NMR 
spectrn were recorded on a Varian XL-200 spectrometer (200 MHz). 
a Varian VXR-400 (400 MHz), or a Bruker AM360 (360 MHz) and 
are reported in units of 6 relative to internal CHCI, at 7,240 ppm 
unless otherwise stated. All NMR spectra were recorded in CDCI,. 
HPLC data were recorded as described [7]; all samples for biological 
testing were free of AZT (CO.Ol%). 
2.1. 3’.Arido-Y-dcoxythynidine-Y-dodccy f (etfty f glycoly!) pltuspltate 
/3al 
This was prepared entirely as recently described by US [6]. 
3.3. 3’-Atido-Y-deoxytlrynlidirle-5’-(etftyf glycofyf) (ntetltyl laclyl) 
p ftosp lute 136 / 
Ethyl glycolyl methyl lactyl phosphorochloridate (1.62 g, 1.5 ml, 
0.006 mol) was addtxl to AZT (0.25 g, 0.94 mmol) and N-methylimi- 
dazole (0.61 g, 0.55 ml, 0.007 mol) in tetrabydrofuran (5 ml) wirh 
stirring at room temperature. After stirring for two days the mixture 
was concentrated to dryness under reduced pressure, dissolved in 
chloroform (30 ml) and washed with saturated sodium bicarbonate 
solution (15 ml) and water (IO ml). The aqueous layers were extra&d 
with chloroform (I 5 ml) and the combined organic layers dried over 
magnesium sulphate (ca. 5 g), Filtration and concentrdlion to a ml1 
volume (ca. 3 ml) followed by precipitation from ptroleum ether (bp 
SO-WC) (500 ml) overnight at -20°C gave an amber gum. Flash 
column chromatography on silica eluted with 0.5% methanol in MO- 
reform gave a colourless gum. This was dissolved in 2-propanol. 
filtered and concentrated under reduced pressure to yield the product 
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as a glass (Oh42 g 86%); &:lfO.l (m, C(O)CH), 167.9 (m, C(O)CH&, 
lG3.6 (C-2), 150.2(C-4), 13S.T(C-6, A), 135.2(C-6. B), 1 ll.S(C-5. A), 
lllXi(C-5, B), 84.6(C-I’), 82.3(d, C-4’, A. J=8.4 He), 82.2(d, C4’, B, 
J=8.3 Hz), 72.75(d, CHO. A, J=S.4 Hz), 72.70(d, CHO, B, J=5.8 Hz), 
67.O(d, C-T’, A , J=S.8 Hz), G6.9(d, C-S, B, J=5.3 Hz), 64.l(d, 
C(O)CHI, B, J=S.I Hz), 63.8(d, C(0)CHI, A, J=S.O Hz), 
61.9(CH20C. A), 61.8(CH20C, B), 60,2(C-3’, A), 60.15(C-3’, B), 
52.7(MeO), 37.53(C-2’. A), 37.49(C-2’, B), 19.07(d, CH$H, 13, J=6.6 
Hz), 18.96(d, Cl-i&H, A, J=6.9 Hz), Irl.l(CH,CH,), 12.41(5-Me, B), 
12.37(5-Me, A); S, -1.605, -2.369, A:B 3:l; b,, 8.81,8.83 (lH, s, NH, 
B, A), 7.49, 7.46(1H, d, H6, A, 6, J=l.3, 1.2 Hz), 6.0(1H, m, H-l’), 
S.O(lH, m, CHO), 4.7(1H, m, H-3’). 4.5(4H, m, H-S, C(O)CH&, 
4.25(2H, q, CH,OC, J=7.1 Hz), 4.1(1H, m, H-43, 3.87, 3.79(3H, 5, 
MeO, A, B), 2.5(2H, m.H-2’), 1.94, 1.93(3H, d, S-Me, A, B, J=l.lf, 
1.19 Hz), 1.6(m, CH,CH, B, A), 1.3(3H, m, CH,CH,); E.I.M.S. m/c: 
519(M+, 2%), 435(0.1), 416(M+-CJH,Os, I), 393(0.4), 386(MH+- 
CJH,03-CH30, 30), 373(MH’-CdH,03-N,H, S), 351(MH*-thymine - 
N3H, 30), 313(M’-C,H,O&H,OJ, I), 271(7). ZSO(AZT.H+-HQ, 18), 
18S(CJH,0>P0,H+ , 3), 167 (45), 149(16). 126(thymine.H+, 25), 87 
(lo), 81(C~H~O+, 100); Found: C 41.45%, H 5.03, N 12.86, P 6.25, 
C,lIHz(IN,O,,P requires C 4i.62%, H 5.05, N 13.48, P 5.96. 
2.3. Y-Azido-Y-deoxythymidine-Y-bis(nlethyi bcryi) phosphate [3c/ 
Bis(mcthy1 Iactyl) phosphorochloridnte was added to AZT (0.10 g 
0.31 mmol) and IY-methylimidazole (0.25 g, 0.24 ml, 0.003 mol) in 
tetmhydrofumn (3 ml) with stirring at room temperature. After stir- 
ring for a furlher 48 h. the mixture was concentrated todryness under 
reduced pressure, dissolved in chloroform (30 ml) und washed with 
saturated sodium bicarbonate solution (15 ml) and then water (IO ml). 
The aqueous layers were cxtracled with chloroform (ca. I5 ml) and Ihe 
combined organic layers dried over magnesium sulphute (IX. 3 g)). 
Filtration and concentration to small volume (ca. 3 ml) under educed 
pressure followed by precipitation of the producl from petroleum 
ether (bp 3e4O’C) (500 ml) overnight at -20°C gave an amber gum. 
Further purification was achieved with flash column chromalogrophy, 
(silica ca. 60 g) cluted with chloroform containing 0.5% methanol. 
Pooling and evaporalion of the appropriate fractions gave a gum. 
(0.17 &88%);6,17Ll(d, C(O)CH, J=3.3 Hz), 170.7(d. C(O)CH, J=3.9 
Hz), 163.9(C-2), 150.5(C-4), 1353(C-6), 11 I.S(C-5). 84.S(C-I’), 82.3(d, 
C-4’, J=8.4 Hz), 72.7(d, CHO J=5.2 Hz). 72.5(d, CHO J=S.l Hz), 
66.6(d. C-S, J=S.9 Hz), 60.3(C-33, 5?.7(MeO), 37.5(C-23, 19.l(d, 
CH$H, J=6.9 Hz), 18.9(d, CH,CH, J=7.l Hz), 12.4(5-MC); L$ 
-2.709; a,, 9,46(1H, s, NH), 7.48(lH, s, H-G), 6.31(IH, t, H-l’, J=6.7 
Hz), S.l(lH, m, CHO), 4.9(1H, m, CHO), 4.5(2H, m, H-5’), 4.5(lH, 
m, H-3’). rf.l{lH, m, H-4’), 3.79(3H, s, MeO), 3.77(3H, s, MeO), 
2.4(1H, m, H-2’), 2.4(IH, m, H-2’), 1.94 (3H, d, S-Me, J=l.2 Hz), 
1.60(3H, dd, C%CH, J= 7.0. I.0 Hz ), 1,58(3H, dd, C&CH, J- 6.9, 
1.0 Hz); E.I.M.S. m/e 519 (M+, 0.9%), 518(0.4), 46O(cO.l), 416(5), 
394(M’-thymine, 0.3), 373(M+-C4H,03-N,H, 9), 351(MH’-thymine- 
N3H, 311, 313(M+-CdH,03, I), 271(2), ZSO(AZT.H’-H>O, l4), 
ISS(C~H~O~PO~H+ , 3), 167(79), 126(thymine.H+, l2), 99(17), 87(25). 
81(CsHJO’, 100); Found C 41.128, H 5.10, N 13.14, P 6.00, 
ClaHmNIOllP requires C 41.62%, H 5.05, N 13.48, P 5.96. 
2.4. Y-Asido-3’-deoxytti~~~~~~d~nc-S’-[ (2,2.2.-rrichtoroethyl) (niethyl 
Imy/)] phosphctie [3d/ 
2,2,2,-Trichloroethyl (methyl aclyl) phosphorochloridete (1.16 g, 
0.88 ml, 0.003 mol) was added to AZT (0.25 p, 0.94 mmol) and 
N-methyliiidazole (0.61 g, 0.60 ml, 0.007 mol) in tetrahydrofuran (S 
ml) with stirring at room lemperaturc. After stirring for two days the 
reacdon mixture was concentrated todryness under educed pressure, 
dissolved in chloroform (30 ml) and washed with saturated sodium 
bicarbonate solution (I 5 ml) and water (10 ml). The aqueous layers 
were back extracted with chloroform (IS ml) and the combined or- 
ganic layers dried over magnesium sulphate (ca. 3 g). Filtration and 
concentration to small volume (ca. 3 ml) followed by precipitation 
from petroleum ether (500 ml) overnight at -20°C gave an amber 
gum. Flash column chromatography on silica clutcd with 0.5% meth- 
anol in chloroform afforded the product as a glass, on pooling and 
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evaporation or ihe appropriate fractions. This was dissolved in 2. 
propanol nnd fillered under reduced pressure. Concentration to dry- 
ness yielded the product as a glass, (0,38 g, 79%); S, 170,5(d, C(O)CH, 
A, J=3.9 Hz), 170.2(d, C(O)CH, B, J=4.2 Hz), lG3.45(C-2, A), 
163,42(C-2, B), 15O.ll(C-4, A), 150.08(C-4, B), 135.2(C-6), I1 1.68(C- 
5, B), 1 I l.SS(C-5, A), 94.8(m, Ccl,), 84.84(C-I’, B), 84.79(C-I’, A). 
82.1(d, C-4’, A, J=8.4 Hz), 82.0(d. C4’, B, J=7.9 Hz), ca. 77(CCl&H3, 
73.1(CHO, B. J=5.5 Hz). 72.l(d, CHO, A, J=5.2 Hz). 67.4(d, C-S’, A, 
J=6.l Hz), 67.l(d, C-5’, B, J=G.O Hz), GO.l(C-3’, A), (iO.O(C-3’, B), 
SZb(MeO), 37.5(C-2’, A), 37.3~~~2’, 6). l8.9(m, CH,CH), 12.5(5-Me); 
S, -1.118, -1.462, A:B 1:3; 6,, 8.78, 8,72(1H, bs, NH, B, A), 7.38, 
7.36(1H, d, H-6, A, 13, J=1.2, 1.2 Hz), 6.2(IH, m, H-l’), S.O(lH, m, 
CHO),4.7,4.6(2H, m, CCl,CB,B, A),4,3(3H,m, H-3’,H-53,4,0(1H, 
m, H-4’), 3.773, 3.770(3H, s, MeO, B, A), 2.4(1H. m, H-23, 2.3(1H, 
m, H-23. 1.92, 1.91(3H, d, S-Me, B, A, J=1.3, 1.2 Hz), I.59,1.57(3H, 
dd, C&CM, J=1.2/7.0, 1.U7.0 Hz). 
2.5. Mureriuts arid experimental procedures: virology 
?.S,l. Anti-HIV-l assay 
We have tested the cytotoxicity and unti-HIV-I activity of the var- 
ious compounds in an anti-HIV assay system which has been dc- 
scribed in detail previously [S]. In this assay system, WC have used 
Molt4 as Ihe target cells which were prc-incubated overnight with the 
compounds being tested, before infection at a multiplicity of I infec- 
tious unit of HIV-I per cell on the following day. This enabled us to 
determine Ihe anti-viral activity and cytotoxicity of the compounds. 
The effects on virus inhibition and cell division arc compared to that 
of AZT at the same time. 
3. RESULTS AND DISCUSSION 
3.1. Chemistry 
Whereas sim$e dialkyl phosphorochloridates react 
relatively rapidly with nucleosides in pyridine at ambi- 
ent temperature [4], the analogous reactions with highly 
substituted phosphorochloridates are rather slow. 
However, a strategy similar to that we have previously 
employed for phosphoramidates [9,10] was found to be 
successful in the case of substituted ialkyl phosphates. 
Thus, as we have recently noted [6] dodecyl (ethyl glyco- 
lyl) phosphorochloridate r acts relatively rapidly with 
AZT (1) in THF at ambient emperature in the presence 
of ZV-methylhzidazole [l 13. The target product (3a) was 
isolated in moderate yield and fully characterised by a 
range of spectroscopic methods. The sample was pure 
by HPLC, and entirely free of any contaminating AZT; 
this is particularly important given the high activity of 
AZT in the biological assay used. 
We have noted the major effect on antiviral activity 
of proceeding from simple dialkyl phosphate derivatives 
of AZT to halogen-substituted dialkyl phosphate!; [S], 
and very recently we have noted the activity of cster- 
substituted alkyd phosphates [6]. However, in the former 
report both alkyl groups were substituted, whilst in the 
latter only one group was ester-containing, the other 
group being a simple alkyl moiety. Thus, it was now of 
interest o prepare the corresponding compounds wieh 
two ester-containing groups. By an analogous route to 
that used for (3a) above, the novel compoilnd with one 
ethyl glycolyl group and one methyl lactyl group (3b) 
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was prepared from AZT in high yield. As with (3a) this 
displayed two signals in the 3LP NMR spectrum, corre- 
sponding to the two diastereoisomers which result from 
mixed stereochemistry at the (chiral) phosphorus cen- 
tre. As previously, these isomers are not produced in a 
1:1 ratio; (3a) displayed a 2: 1 preponderance of the 
down-field isomer, whilst the ratio is 3:1 for (3b). The 
magnitude of the splitting is also greater in the case of 
(3b) (46 0.8 ppm), and the position of the peaks is 
slightly further up-field. The latter might be expected on 
the basis of the increased substitution at the phosphate 
centre [12]. Compound (3b) was fully characterised by 
13C and ‘H NMR, mass spectrometry and microanaly- 
sis. The presence of diastereoisomers was also evident 
from the “C NMR; indeed the 3:l ratio of isomers 
allowed an un-equivocal assignment of many of the 
signals to each of the two structures. As we have noted 
[9,14], it may well be that the individual diastereoisom- 
ers in a particular case may differ in their biological 
activities; however, in this study the mixtures of isomers 
were not separated, and were tested as such. 
We have recently noted the apparent preference for 
ethyl glycolyl over methyl actyl side-chains in the case 
of simple phosphate derivatives of AZT; compounds 
with only one ester-containing group [6], It was of inter- 
est to determine whether the same preference applied to 
more substituted structures uch as (3b). Thus, the sym- 
metrical bis(methy1 lactyl) compound (3e) was prepared . 
using ana!ogol;s che*m:stry. The 3’? NMR of this sample 
clearly revealed the presence of only one isomer; entirely 
as would be expected for such a (symmetrical) phos- 
phate. The position of the 3’P resonance was rather 
similar to that noted for (3b). Other data were also 
similar to the previous compounds, except that again 
they revealed only one compound to be present. 
Finally, it was of interest o examine whether other 
substituted groups would be equally effective, besides 
ester-containing groups. We have already reported the 
activity of bis(trihaloethy1) phosphate derivatives of 
AZT and other nucleosides [5]. It was therefore reason- 
able to examine the effects of such a group in combina- 
tion with an ester-containing group. Thus, the trichlo- 
roethyI (methyl actyl) phosphate of AZT (3d) was pre- 
pared following our established synthetic route. Again, 
two isomers were noted in the 31P NMR; though the 
up-field isomer now predominated. Carbon-13 NMR 
data also confirmed the structure, purity, and isomeric 
constitution of (3d). 
3.2. htivirul activity 
The effect of various concentrations of (1) and (3ad) 
on HIV-1 replication are outlined in Table I. Intcrest- 
ingly, despite the differences between this assay and that 
previously used [6,13] compound (3a) was of rather sim- 
ilar activity in both assay systems. Moreover, compar- 
ing (3a) to (3b-e) it appears that the presence of two 
ester-substituted groups enhances activity approxi- 
mately lOO-fold, relative to having only one substituted 
group; although this cannot be precisely defined given 
the different structures of the esters. However, the iden- 
tical activity of (3b) and (3~) indicates no difference 
between ethyl glycolyl and methyl lactyl groups in this 
series; unlike the case with one ester-containing group 
[6]. Lastly, the intermediate activity of @I), being ap 
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Compound Dosage Estimated cell Estimated anti-HIV 
(@ml) growth in %* activity in 8’ 
I 10 10 100 
I 40 100 
0.1 80 100 
0.01 100 90 
3a 100 SO 100 
10 70 90 
I 90 60 
3b 100 80 100 




500 40 100 
100 60 100 
IO 90 IO0 
1 100 100 
0.1 100 90 
Sd 100 20 100 
10 80 100 
1 loo 90 
l % of cell growth compared to cells grown in the absence of drug 
counted on day IO. 
3e 
Table 1 
Cytotoxicity and anti-HIV1 activity 
+% of cells not stained for HIV antigen by immunopcroxidase m thod 
nt day IO. 
proximately lo-fold less active than (3b-c), suggests 
that a trihaloethyl group may substitute for an ester- 
containing group, but with reduced potency. 
Compound (3a) is of low antiviral selectivity; being 
toxic to uninfected cells even at high dilution. On the 
other hand, compounds (3b-c) are very selective inhib- 
itors of viral proliferation. Both are at least loo-times 
less toxic than the parent nucleoside. Since they are only 
lo-times less active than the nucleoside, the therapeutic 
index of (3b-e) is at least lo-times that of AZT in this 
assay system. The origins of this reduced toxicity are 
uncertain, but this may be consistent with a mode of 
action involving slow intracellular elease of phosphate 
derivatives of AZT, rather than the free nucleoside. 
In conclusion, we have reported the synthesis and 
anti-HIV evaluation of a series of novel ester-containing 
phosphate derivatives of AZT. The compounds how a 
range of activities, but are generally less active than 
AZT, but also less toxic. They display much greater 
antiviral selectivity than the parent nucleosidc. The data 
are consistent with a mode of action involving intracel- 
lular release of the bio-active free nucleotides. If these 
in vitro findings could be translated into a demonstrable 
in vivo advantage, such phosphate pro-drugs could 
have merit as candidates for clinical development. 
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